Top Markets
Coin of the day
Ortin Laboratories Limited Ortin Laboratories Limited

Ortin Laboratories Limited

ORTINLAB
Rank in Stocks #37115
Ortin Laboratories Limited, a pharmaceutical company established in Hyderabad,... Ortin Laboratories Limited, a pharmaceutical company established in Hyderabad, India, in 1986, is engaged in the manufacturing and commercialization of a diverse range of medicines, drugs, and chemical intermediates. The company provides a wide array of pharmaceutical formulations, presented as tablets, capsules, syrups, and dry powders. These products target various therapeutic domains such as metabolic diseases (e.g., anti-diabetics), allergic reactions, infections (including broad-spectrum antibiotics and antifungals like quinolones, penicillins, cephalosporins, macrolides, and antifungals), pain management and fever reduction (analgesics and antipyretics), cardiovascular ailments (anti-anginal and cardiovascular products), digestive system disorders (antacids and anti-ulcerants), neurological and psychiatric conditions (sedatives, tranquilizers, psychiatry products), and nutritional supplementation (like vitamins, calcium, iron, and protein supplements). Specialized offerings also include anti-retroviral, anti-arthritic, anti-helminthic, anti-spasmodic, gynaec, appetite stimulators, and chemotherapeutic preparations. In addition to finished pharmaceuticals, Ortin produces active pharmaceutical ingredient (API) intermediates for applications such as anti-retrovirals, anti-diabetics, pain and fever medications, antibiotics, antifungals, antacids, anti-malarials, and anti-ulcerants. Its manufacturing capabilities also extend to fine chemicals and Grignard/alkali metal compounds. The company offers specialized services covering process development and characterization, analytical research, assay development, and product characterization. It also contributes to diagnostics through the development of rapid flow kits, assays, and reagents. Ortin Laboratories undertakes long-term contracts for the production of intermediates and the creation of novel APIs. Moreover, it actively functions as a merchant exporter of its finished pharmaceutical products.
Share Price
$0.2488447
Last synced: 2024-10-01
Market Cap
$2.01M
Change (1 day)
-1.88%
Change (1 year)
0.00%
Country
IN
Trade Ortin Laboratories Limited (ORTINLAB)

Category

P/E ratio for Ortin Laboratories Limited (ORTINLAB)
P/E ratio as of August 2026 TTM: -17.26
According to Ortin Laboratories Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -17.26. At the end of 2023 the company had a P/E ratio of -213.31.
P/E ratio history for Ortin Laboratories Limited from 2008 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -17.26 827.97%
2024 -1.86 -99.13%
2023 -213.31 362.83%
2022 -46.09 -272.46%
2021 26.72 -227.08%
2020 -21.03 -211.11%
2019 18.93 -58.98%
2018 46.14 -42.43%
2017 80.15 128.70%
2016 35.05 42.33%
2015 24.62 32.07%
2014 18.64 -8.57%
2013 20.39 17.19%
2012 17.40 16.12%
2011 14.98 137.07%
2010 6.32 -14.89%
2009 7.43 42.83%
2008 5.20 0.00%
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.